welcomes you to the new, improved website!This randomized trial evaluating the relative efficacy of immunotherapy and chemotherapy in patients with recurrent or metastatic disease, immunotherapy was associated with significantly better progression-free survival. Tumor mutational burden was a marker for patient selection for immunotherapy.
You are here:
Nivolumab Plus Ipilimumab in Lung Cancer With a High Tumor Mutational Burden
Submitted by: Mark Ferguson
Source: The New England Journal of Medicine
Keywords:
Author(s): Matthew D. Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong Seok Lee, Gregory A. Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak Burgers, Pamela Salman, Hossein Borghaei, Suresh S. Ramalingam, Julie Brahmer, Martin Reck, Kenneth J. O’Byrne, William J. Geese, George Green, Han Chang, Joseph Szustakowski, Prabhu Bhagavatheeswaran, Diane Healey, Yali Fu, Faith Nathan, Luis Paz-Ares
